{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice Zelluna Immunotherapy (Zelluna), located in Oslo, Norway.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/03/30/2021-06475.html","cfr_references":[],"citation":"86 FR 16603","comment_url":null,"comments_close_on":"2021-04-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 14, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-06475","effective_on":null,"end_page":16604,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/03/30/2021-06475.xml","html_url":"https://www.federalregister.gov/documents/2021/03/30/2021-06475/prospective-grant-of-an-exclusive-patent-license-the-development-of-natural-killer-nk-cell","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-06475?publication_date=2021-03-30","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-03-30/2021-06475/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":366,"last_updated":"2026-07-26 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-03-30/pdf/2021-06475.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-06475.pdf?1617021921","publication_date":"2021-03-30","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/03/30/2021-06475.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:32:22Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":16603,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: The Development of Natural Killer (NK) Cell Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) T Cell Receptor (TCR) Therapy for the Treatment of KK-LC-1 Expressing Human Cancers","toc_doc":"The Development of Natural Killer Cell Kita-Kyushu Lung Cancer Antigen 1 T Cell Receptor Therapy for the Treatment of KKLC1 Expressing Human Cancers","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}